CARsgen Therapeutics Holdings Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States. The company is involved in developing CT053, an autologous CAR-T product candidate that is in pivotal Phase II trial for the treatment of relapsed/refractory multiple myeloma in China; CT041, an autologous CAR-T product candidate that is in Phase Ib/II clinical trial for advanced gastric/gastroesophageal junction cancer and pancreatic cancer in China, as well as in Phase Ib clinical trial for advanced gastric or pancreatic cancer in the United States; and CT011, an autologous CAR-T product candidate that is in Phase I clinical trial for patients with Glypican-3 positive advanced hepatocellular carcinoma. It is also developing CT032, an autologous CAR-T products candidate that is in Phase I/II clinical trial for the treatment of B cell Non-Hodgkin's lymphoma in China; AB011, a humanized monoclonal antibody product candidate that is in Phase I clinical trial for the treatment of CLDN18.2 positive solid tumors in China; and CT017, an autologous Glypican-3-targeted CAR-T product candidate for the treatment of hepatocellular carcinoma, as well as other product candidates for the treatment of solid tumors. The company was founded in 2014 and is headquartered in Shanghai, China.

CARsgen Therapeutics Holdings Limited

CARsgen Therapeutics is a biopharmaceutical company with operations in China and the U.S. focused on developing innovative CAR T-cell therapies for the treatment of hematological malignancies and solid tumors.

CARsgen Therapeutics

CARsgen is a biopharmaceutical company with operations in China and the U.S. focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors. The company has built an integrated cell therapy platform with in-house capabilities that span target discovery, antibody development, clinical trials, and commercial-scale manufacturing. CARsgen has internally developed novel technologies and a product pipeline with global rights to address major challenges of CAR T-cell therapies, such as improving the safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs. Our vision is to become a global biopharmaceutical leader that brings innovative and differentiated cell therapies to cancer patients worldwide and makes cancer curable.

Media contact: pr@carsgen.com

JIC Genesis Fountain Healthcare Ventures

Kaitai Capital

Summer Capital

Lilly Asia Ventures

Loyal Valley Capital

Shiyu Capital

South China Venture Capital

Photon Fund

Jolly Innovation Ventures

KTB Ventures

"In the past six months, we have made significant progresses in technological innovation, product development, and business operations. Zevor-cel was successfully launched in China and has been included in nearly 20 provincial and municipal healthcare plans. The pivotal Phase II trial of satri-cel in China has completed patient enrollment. We are also actively exploring the potential of satri-cel in adjuvant therapy, aiming for greater clinical benefit for patients. Additionally, we are rapidly advancing CT071, which is manufactured with our CARcelerate® platform, while continuing to develop multiple allogeneic CAR T-cell products based on the THANK-uCAR® platform." said Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen Therapeutics.

https://lnkd.in/gmubHD2Y

#cartcelltherapy #biotech #hematology #oncology

"We are very pleased to announce the successful completion of patient enrollment in the pivotal Phase II clinical trial of satri-cel in China. This significant milestone marks another solid step forward in our development of CAR T-cell therapies for solid tumors. We extend our gratitude to all the investigators, the patients and their families for their trust and support. We look forward to the submission of New Drug Application and the approval in China, to benefit patients with gastric cancer. As one of the leading companies in the field of CAR T-cell therapies, we remain committed to addressing the major challenges faced by existing CAR T-cell therapies and will develop more innovative CAR-T products for cancer patients." said Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen Therapeutics.

https://lnkd.in/gZjZdQZa

The updated results of zevorcabtagene autoleucel (zevor-cel; R&D code: CT053, an autologous CAR T-cell product targeting BCMA) and CT071 (an autologous CAR T-cell product targeting GPRC5D) have been presented at the 29th Annual Congress of the European Hematology Association (“EHA”). 

https://lnkd.in/gEKkNrwb

#cartcelltherapy #eha2024 #multiplemyeloma #bcma #gprc5d #carcelerate

The preliminary results of Phase I of CT071 (NCT05838131) were presented as a poster at the 29th EHA Annual Congress on June 14, 18:00 - 19:00 CEST, which was titled "First-in-human study of GPRC5D-targeted CAR T cells (CT071) with an accelerated manufacturing process in patients with relapsed/ refractory multiple myeloma (RRMM)"

https://lnkd.in/g3R_eYun

#eha #eha2024 #rrmm #cartcelltherapy #gprc5d

The final follow-up results of the investigator-initiated trial CT041-CG4006 (NCT03874897) of satricabtagene autoleucel ("satri-cel", CT041) (an autologous CAR T-cell product candidate against Claudin18.2) have been published in Nature Medicine on June 3, 2024. Data were presented as an oral presentation at the 2024 American Society of Clinical Oncology ("ASCO") Annual Meeting.

https://lnkd.in/gnsCAqeq

The FDA has granted IND clearance for CT071, an autologous CAR T-cell therapy candidate targeting GPRC5D, for the treatment of patients with relapsed/refractory multiple myeloma (MM) or relapsed/refractory primary plasma cell leukemia (PCL).

CT071 is manufactured with CARsgen's proprietary CARcelerate™ platform, which shortens the manufacturing time to less than 2 days and therefore yields younger, healthier, and possibly more potent CAR T cells compared to conventional manufacturing. 

https://lnkd.in/gjx2kUiH

#cartcelltherapy #GPRC5D #CARcelerate

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue			25.81M -
cost of revenue
gross profit			25.81M -
selling and marketing expenses					5.47K -
general and administrative expenses	8.75M -	54.80M 526.14%	65.82M 20.10%	46.82M 28.86%	127.84K 99.73%
selling general and administrative expenses	8.75M -	54.80M 526.14%	65.82M 20.10%	46.82M 28.86%	133.31K 99.72%
research and development expenses	210.20M -	281.75M 34.04%	501.72M 78.07%	680.30M 35.59%	661.66K 99.90%
other expenses	11.41M -	12.12M 6.22%	44.27M 265.34%	75.16M 69.79%
cost and expenses	230.36M -	348.67M 51.36%	611.80M 75.47%	802.28M 31.13%	815.51K 99.90%
operating expenses	230.36M -	348.67M 51.36%	611.80M 75.47%	802.28M 31.13%	815.51K 99.90%
interest expense	887K -	13.48M 1,419.73%	10.87M 19.37%	15.52M 42.80%
ebitda	-206.40M -	-286.17M 38.65%	-517.89M 80.97%	-793.90M 53.29%	-715.42K 99.91%
operating income	-227.40M -	-327.05M 43.82%	-585.99M 79.18%	-881.30M 50.39%	-785.05K 99.91%
depreciation and amortization	21.00M -	40.87M 94.65%	68.10M 66.61%	87.40M 28.34%	69.63K 99.92%
total other income expenses net	-37.73M -	-737.00M 1,853.21%	-4.15B 463.20%	-9.65M 99.77%	37.66K 100.39%
income before tax	-265.13M -	-1.06B 301.33%	-4.74B 345.17%	-890.95M 81.19%	-747.39K 99.92%
income tax expense	39.16M -	737.77M 1,783.88%	7.64M 98.96%	1.29M 83.06%	407 99.97%
net income	-304.30M -	-1.80B 492.13%	-4.74B 163.31%	-892.25M 81.19%	-747.79K 99.92%
weighted average shs out	567.35M -	567.35M 0%	386.83M 31.82%	551.63M 42.60%	556.13K 99.90%
weighted average shs out dil	567.35M -	567.35M 0%	386.83M 31.82%	551.63M 42.60%	556.13K 99.90%
eps	-0.54 -	-3.18 488.89%	-12.26 285.53%	-1.62 86.79%	-1.34 17.28%
epsdiluted	-0.54 -	-3.18 488.89%	-12.26 285.53%	-1.62 86.79%	-1.34 17.28%

2171

COM:CARSGEN

CARsgen Therapeutics

Last Close

7.02

25/11 08:08

Market Cap

2.36B

Beta: -

Volume Today

8.53M

Avg: -

Preview